Senseonics Holdings, INC 8-K filings

Senseonics Holdings, Inc. announced record second quarter 2026 revenue of $14.5 million, a 120% year-over-year increase, and raised its full-year revenue and gross margin guidance.

Senseonics Holdings, Inc. announced the closing of asset purchase agreements for its Eversense CGM activities in Germany, Spain, Sweden, and Italy.

Senseonics Holdings, Inc. stockholders approved an amendment to increase authorized common stock from 70 million to 140 million shares, effective May 20, 2026.

Senseonics Holdings, Inc. announced first quarter 2026 financial results, showcasing an 87% year-over-year revenue increase to $11.7 million and raising its full-year revenue guidance.

Senseonics Holdings, Inc. has amended its loan agreement, potentially accessing up to $140 million in senior secured term loans, with initial tranches expected to close May 6, 2026.

Senseonics Holdings, Inc. finalized agreements to acquire commercial Eversense CGM assets in key European territories, aiming to expand direct operations.

Senseonics Holdings, Inc. announced robust fourth quarter and full year 2025 financial results, driven by significant revenue growth and strategic commercialization efforts.

Senseonics Holdings, Inc. announced preliminary unaudited record revenue for Q4 and full year 2025, alongside robust 2026 guidance and key operational advancements.

Senseonics Holdings, Inc. is acquiring commercial assets for its Eversense product from Ascensia Diabetes Care, taking direct control of U.S. and European sales.

Senseonics Holdings, Inc. reported a 90% year-over-year revenue increase to $8.1 million in Q3 2025, driven by strong U.S. patient growth, and announced plans to transition commercial responsibility for Eversense back from Ascensia Diabetes Care.

Senseonics Holdings, Inc. has filed an amendment to its Certificate of Incorporation to effect a one-for-twenty reverse stock split and a proportional reduction in authorized common shares.

Senseonics Holdings, Inc. announced preliminary unaudited third-quarter 2025 revenue of approximately $8.1 million, marking a 91% increase year-over-year.

Senseonics Holdings, Inc. announced preliminary unaudited third-quarter 2025 revenue of $8.1 million, a 91% increase year-over-year, alongside a 1-for-20 reverse stock split effective October 17, 2025.

Senseonics Holdings, Inc. stockholders approved a proposal granting the Board of Directors authority to effect a reverse stock split in a range of 1-for-10 to 1-for-20.

Senseonics Holdings, Inc. announced a strategic shift to directly manage Eversense CGM commercialization and secured an expanded $100 million debt facility from Hercules Capital.

Senseonics Holdings, Inc. announced robust second quarter 2025 financial results, driven by significant U.S. patient growth and strategic advancements.

Senseonics Holdings held its annual meeting on May 21, 2025, and stockholders voted on key proposals, including the election of directors and ratification of the company's executive compensation and independent auditor.

Senseonics Holdings amends its previous 8-K filing to update exhibits related to a common stock offering of 115,000,000 shares.

Senseonics Holdings, Inc. announces a public offering of common stock and a concurrent private placement to Abbott Laboratories, aiming to raise funds for Eversense 365 launch, pipeline development, and general corporate purposes.

Senseonics Holdings, Inc. has entered into a securities purchase agreement with Abbott Laboratories for a private placement of up to $25 million of its common stock, contingent upon a proposed public offering.

Senseonics Holdings, Inc. announced a 24% year-over-year increase in revenue for Q1 2025, driven by the adoption of its Eversense 365 continuous glucose monitoring (CGM) system and progress in strategic partnerships.

Senseonics Holdings, Inc. announced its Q4 and full year 2024 financial results, highlighting FDA approval and launch of Eversense 365, a 56% increase in patient base, and a positive outlook for 2025.

Anthony Raab resigned from the Senseonics Holdings Board of Directors effective January 17, 2025, to focus on his investment career and other commitments.

Senseonics reported preliminary 2024 financial results, highlighted the successful launch of Eversense 365, and cancelled a special meeting regarding a proposed reverse stock split.

Senseonics presented at the Stifel 2024 Healthcare Conference, showcasing the commercial launch of Eversense 365 and outlining future product development.

Senseonics announced its third quarter 2024 financial results, highlighted by the FDA approval and initial commercial launch of its Eversense 365 continuous glucose monitoring system.

Senseonics Holdings, Inc. has announced a $16 million registered direct offering of common stock, with the potential for an additional $16 million through the exercise of warrants.

Senseonics Holdings, Inc. announced an 18% year-over-year revenue increase for the second quarter of 2024, alongside progress in the development and launch of their next-generation 365-day continuous glucose monitoring system.

Senseonics reaffirms first half 2024 revenue, reports significant new patient growth, and provides full year 2024 financial outlook.

Senseonics Holdings has increased its authorized common stock shares from 900 million to 1.4 billion following approval at its 2024 Annual Meeting of Stockholders.